Background: The CHA(2)DS(2)-VASc score is often used for stroke risk stratification in atrial fibrillation (AF) patients. However, its usefulness in patients >= 75 years of age with or without AF is unclear. Objective: We aimed to investigate whether the CHA(2)DS(2)-VASc score can predict ischemic stroke (IS), transient ischemic attack, thromboembolism (TE), and mortality in elderly patients with and without AF. Materials and methods: During 2013-2014, 1,071 patients (36.3% with concomitant AF) at least 75 years old were enrolled, and the follow-up ended on July 15, 2017. Variables included sociodemographic characteristics, complications, drugs taken, laboratory results, and echocardio-graphic parameters. The primary end points were IS, transient ischemic attack, and TE, expressed as IS/TE. All-cause mortality was a secondary end point. Survival curves and mortality risks were assessed via Kaplan-Meier survival analysis and compared by log-rank tests. Results: The average follow-up duration was 2.57 +/- 1.37 years. Overall, 167 patients (5.6%) died and 77 (7.2%) developed IS/TE. The CHA(2)DS(2)-VASc score was associated with IS/TE in patients 75 years or older with and without AF, and patients with a CHA(2)DS(2)-VASc score >5 had a higher risk of stroke. However, the CHA(2)DS(2)-VASc score was not related to all-cause mortality. Conclusion: The CHA(2)DS(2)-VASc score can predict IS/TE, but not mortality, in elderly patients (>= 75 years) with or without AF.